Bacillus Subtilis W700에서의 Staphylpkinase 대량생산을 위한 배지 최적화 및 배양방법의 비교

Media Optimization and Comparison of Fermentation Type for Overproduction of Staphylodinase in Bacillus subtilis WB700

  • 박인석 (서울대학교 공과대학 응용화학부 및 유전공학연구소) ;
  • 김병기 (서울대학교 공과대학 응용화학부 및 유전공학연구소)
  • Published : 2001.08.01

Abstract

Bacillus subtilis WB700에서 P43 프로모터를 사용하여 staphylokinase를 생산하기 위하여 배지 최적화 및 회분식 배양과 유가식 배양 두가지 시스템을 비교하였다. 여러 가지 질소윈 중에서는 tryptone이 가장 좋은 질소원 이었으며, MSR 배지를 사용한 경우 tryptone 15 g/L일 경우에 최적조건임을 알아내었다. MSR 배지에시 포도당을 제한 기질로 사용할 경우는 5 g/L일 때가 SAK의 발현에 최적 조건이었다. MSR 배지를 기본으로 이용하여 포도당 공급을 조절함으로서 발효조 내의 DO를 30%로 유지한 결과 오히려 MSR 배지를 이용하여 회분식 발효를 한 경우보다 좋지 못한 결과를 얻었으며, 이는 B. subtilis 숙주의 영양요구적 특이성과 P43 promoter의 stress 발생시 주 발현되는 특성 등에 기인한 것이라고 사료된다. MSR 배지를 이용하여 회분식 발효를 하였을 때 SAK 활성은 2880 unit이었고, 이때 배지 내로 분비된 SAK 농도는 455 mg/L이었다.

To produce staphylokinase (SAK) in B. subtilis WB700, media optimization was carried out and the operation of batch and fed-batch fermentation were compared. Tryptone is a good nitrogen source and its optimum concentration in modified super rich(MSR) media is 15 g/L. When glucose is used as a limiting carbon source in the MSR media, 5 g/L of an optimum glucose concentration was identified for the SAK production under the control of P43 promoter. As the expression of P43 promoter is controlled by the limitation of oxygen, the SAK production was controlled at the 30% DO level in the fed-batch fermentation. Unexpectedly, batch fermentation using MSR media showed 1.5 times higher yield of SAK than that of the fed-batch fermentation. The main cause of the results comes from not achieving higher cell concentration in the fed-batch fermentation and the optimum expression level of P43 promoter under oxygen or nutrient limitations. We could not achieve the increase in cell concentration by any means in batch culture as well as fed-batch culture. The highest yield in the batch culture was 2880 units of SAK activity and 455 mg/L of secreted SAK.

Keywords

References

  1. Seminars in thrombosis and hemostasis v.17 Fibrinolytic:Biochemical Mechanism Robbins,K.C
  2. Blood v.84 Staphylokinase a fibrin-sfecific plasminogen activator with therapeutic potential Collen,D.;H.R.Lijnen
  3. Circulation v.87 Comparative immunogenicity and thrombolytic properties towards arterial and veous thrombi of streptokinase and recombinant staphylokinase in baboons Collen,D.;F.De Cock;JM.Stassen
  4. Bio/Technology v.12 High Yield Production and purification of recombinant staphylokinase for thrombolytic therapy Schlott,B.;M.Hartmann;KH Guhrs;E.Birch-Hirschfeid;HD Pohl;S.Vanderschueren;F.V.D.Werf;A.Micoel;D.Collen;D.Behnke
  5. Circulation v.92 Thrombolytic therapy of peripheral arterial occlusion with reconbinant staphylokinase Vanderschueren,S;L.Stockx;G.Wilms;H.Lacroix;R.Verhaeghe;J.Vermylen;D.Collen
  6. Eur.J.Biochem v.149 Overproduction of staphylokinase in Escherichia coli Sako,T.
  7. Mol.Gen.Genet v.210 Cloning and expression in Escherichia coli,Bacillus subtilis,and Streptococcus sanguis of a gene for staphylokinase-A bacterial plasminogen activatior Behnker,D.;D.Gerlach
  8. Zbl.Bakt.Mikrobiol.Hyg.A. v.269 Purification and characterization of the bacterial plasminogen activator staphylokinase secreated by a recombinant Bacillus subtilis Gerlach,D.;R.Kraft;D.Behnke
  9. Biotechnol.Bioeng v.62 High-level secretory production of intact,biologically active staphylokinase from Bacillus subtilis Ye,R.;J.H.Kim;B.G.Kim;S.Szarka;E.Sihora;S.L.Wong
  10. Korean J.Biotechnol.Bioeng v.9 Development and characterization of sporulation mutants for overexpression of recombinant protein of Bacillus subtilis Oh,M.G.;S.H.Park;B.G.Kim
  11. Unpublished data
  12. J.Biol.Chem v.259 Overlapping promoters transcribed by Bacillus subtilis ${\sigma}^{55} and {\sigma}^{37}$ RNA polymerase holoenzyme during growth and stationary phases Wang,P.Z.;R.H.Doi